Backgrounds. Malignant peripheral nerve sheath tumors (MPNSTs) are an aggressive and often lethal sarcoma that frequently develops in patients with neurofibromatosis type 1 (NF1). We developed new preclinical MPNST models and tested the efficacy of oncolytic herpes simplex viruses (oHSVs), a promising cancer therapeutic that selectively replicates in and kills cancer cells.
Malignant peripheral nerve sheath tumors (MPNSTs) are rare, highly aggressive soft-tissue sarcomas arising in peripheral nerves, with very poor prognosis and resistance to traditional chemotherapy or radiation.
1,2 The current standard of care is surgical resection, which is often incomplete or accompanied by significant loss of function, in conjunction with radiotherapy and/or chemotherapy, for which the benefits are inconclusive. 1, 3 About 50% of MPNSTs develop in patients with neurofibromatosis type 1 (NF1), a frequently occurring autosomal dominant genetic disease, which affects about 1:4000 births. 2,4 -6 The NF1 gene product, neurofibromin, contains a Ras-GTPase activating protein domain that negatively regulates Ras activity. 7 In MPNST, loss of heterozygosity of NF1 occurs, with tumors that have constitutively activated Ras. 8 Because of the relative rarity of MPNST and the limited patient population compared with other cancers, it is difficult to conduct randomized controlled clinical trials or to evaluate the increasing number of potential therapeutic agents in patients. Therefore, preclinical models are very important in identifying and prioritizing agents for clinical translation. A number of genetically engineered mouse models have been developed in which high-grade peripheral nerve sheath tumors arise that are histologically similar to human MPNSTs. 9 This includes the initial cis-linked Nf1 +/2 / Trp53 +/2 model. 10, 11 MPNST cells isolated from tumors arising in these mice have been used as models in immunodeficient mice, but not in immunocompetent mice until now. 12, 13 An additional avenue for preclinical modeling takes advantage of cancer stem cells that have been isolated from a number of solid tumors, often by sphere formation in serum-free media with growth factors, 14 including from a variety of sarcomas. 15 -19 We recently established MPNST stemlike cells (MSLCs) from a human MPNST cell line. 20 These MSLCs form spheres in media with epidermal growth factor (EGF) and basic fibroblast growth factor (FGF) that can self-renew, form secondary spheres from single cells, express stem cell markers, and differentiate into multiple lineages in serum or lineage-specific growth factors. 20 Here we describe a new orthotopic tumor model generated from sciatic nerve implantation of these human MSLCs.
Oncolytic herpes simplex viruses (oHSVs) are genetically engineered to replicate selectively in cancer cells-killing them, generating more virus, and spreading within the tumor. 21 In addition to direct cell killing, oHSV also induces a robust antitumor immune response. 22 Oncolytic HSVs, containing a variety of mutations, have proven very effective in treating tumors in mouse models. 21, 23 This has led to a number of clinical trials, including a phase III trial for melanoma. 24 Because of their size, oHSV can be "armed" with therapeutic transgenes-including immunomodulatory, antiangiogenic, and cytotoxic genes-that are expressed in the tumor after infection. 25, 26 In these studies we use G47D, a thirdgeneration oHSV 27 that is efficacious in treating nervous system tumors and cancer stem cells. 28 -30 To enhance activity, G47D has been "armed" with interleukin (IL)-12 or platelet factor 4 (PF4). 13, 31 Interleukin-12 is a heterodimeric proinflammatory cytokine that promotes type 1 T helper cell immune responses, interferon (IFN)-g production, and anti-angiogenesis.
32 PF4 (CXCL4), a heparin-binding tetramer, inhibits angiogenesis and the binding of growth factors (FGF and vascular endothelial growth factor) to their receptors and activates natural killer cells and nonspecific antitumor immune responses. 33, 34 We previously reported that G47D-PF4 inhibited the growth of subcutaneous M2 MPNSTs in immunodeficient mice. 13 In this study, we describe 2 new orthotopic sciatic nerve MPNST models: (i) mouse MPNST cell lines derived from spontaneously arising tumors in transgenic mice implanted into immunocompetent mice and (ii) human MSLCs implanted into immunodeficient mice. This is the first report of an MSLC tumor model and an immunocompetent MPNST implant model. G47D was very effective at treating both tumor models, and arming oHSV with IL-12 or PF4 improved activity in immunocompetent mice.
Materials and Methods

Cells and Viruses
Mouse MPNST cells derived from spontaneously arising tumors in Nf1/ Trp53 heterozygous mice were obtained from the Luis Parada Lab (University of Texas Southwestern Medical School) 10 and cultured in Dulbecco's modified Eagle's medium (DMEM; Cellgro), 10% fetal calf serum (HyClone), streptomycin (100 mg/mL), and penicillin (100 U/mL; Cellgro) as monolayers at 378C in an atmosphere of 5% CO 2 . We have renamed the cells for ease of identification: M1 ¼ 61E4, M2 ¼ 37-3-18-4, M3 ¼ 35-1-2, M4 ¼ 38-2-18, M5 ¼ 39-2-11, and M6 ¼ 32-5-24-12. Some of these have been previously described. 35, 36 Human S462 MSLCs 20 were cultured in Neurobasal media supplemented with 3 mM L-Glutamine (Mediatech), B27 supplement (Invitrogen), N2 supplement (Invitrogen), 2 mg/mL heparin (Sigma), 20 ng/mL recombinant human EGF (R & D systems), 20 ng/ mL recombinant human FGF2 (Peprotech), and 0.5× penicillin G/streptomycin sulfate/amphotericin B complex (Mediatech), in ultra-low attachment flasks (Corning) at 378C in an atmosphere of 5% CO 2 . All cells were used at low passage number and confirmed to be mycoplasma free (LookOut Mycoplasma kit, Sigma). Grown, purified, and titered on Vero cells (obtained from American Type Culture Collection) were oHSVs G47D (g34.5D, ICP6
2 , ICP47D, LacZ + ), G47D-empty (no transgene), armed G47D-mCherry (expressing mCherry), G47D-PF4 (expressing PF4), and G47D -IL12 (expressing IL-12) as previously described. 37 Armed oHSVs ( Supplementary Fig. S1 ) were constructed using the Flip-Flop HSV bacterial artificial chromosome system 38 as previously described.
13,31
Animal Models 5 in 2 mL) were implanted into the surgically exposed left sciatic nerve of female C57BL6/129SVSVImJ mice (as described) or female athymic mice 8 weeks old (NCI-Frederick), respectively, using a 30G needle and 10-mL Hamilton syringe. To evaluate tumor growth, left hind-limb function was evaluated twice a week using a neurologic scoring system we developed, measuring 5 parameters scored from 0 (abnormal) to 2 (normal) as illustrated in Supplementary Fig. S4 . For the safety study, G47D or phosphate buffered saline (PBS) was injected directly into the sciatic nerve of non -tumor bearing athymic mice. Mice were weighed and their neurologic scores determined. At indicated days, mice were sacrificed and perfused with fixative (see Histology).
Treatment of Sciatic Nerve Tumors
At a time when tumors were established (typically when neurologic deficit was exhibited; as in Fig. 3A ), mice were randomized into groups and virus treatment initiated (day 0). The tumor-bearing sciatic nerve was surgically exposed, and virus (dose indicated in legend) or PBS in 2 mL was injected using an intracranial catheter (Braintree Scientific) and syringe pump (80 mL/h). In some cases, tumors were treated with 2 injections. Tumor measurements were performed every 3 -4 days with calipers; tumor volume (mm 3 ) ¼ width 2 ×length/2. Mice were sacrificed when tumors reached 18 mm in maximal diameter or mice were unable to reach food or water.
Histology and X-Gal Staining
Tumors were removed after intracardiac perfusion (ice cold PBS, pH 7.3 [Cellgro]) followed by fixative (2% paraformaldehyde, 5 mM EDTA, 2 mM MgCl 2 in 0.1 M piperazine-N,N ′ -bis(2-ethanesulfonic acid), pH 7.3 [Calbiochem]), then were placed in fixative for an additional hour and submersed with cold PBS overnight. For X-Gal staining en bloc, tumors were incubated with X-Gal (Cellgro) 1 mg/mL, 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, 2 mM MgCl 2 , 0.01% sodium deoxycholate (Sigma), and 0.02% NP-40 (nonyl phenoxypolyethoxylethanol; Sigma) in PBS, pH 7.3, for 3 h at 328C. For sectioning, tumors were washed 30 s in H 2 O at room temperature, 15 min in PBS at 328C, 5 min in H 2 O at 328C, and 30 min in PBS at 48C, submersed in 30% sucrose/2 mM MgCl 2 in PBS overnight at 48C, and frozen in optimal cutting temperature compound (OCT; Sakura Finetek), and 20-mm sections were obtained with a Leica CM300 cryostat microtome. Sections were stained again with Antoszczyk et al.: oHSV treatment of sciatic nerve MPNST X-Gal solution and counterstained with hematoxylin and eosin (Fisher Scientific). In some cases, tumors were removed and fixed in 4% paraformaldehyde (Electron Microscopy Sciences), then 30% sucrose in PBS overnight at 48C, frozen in OCT, and prepared in 20-mm sections.
Electron Microscopy
Nerves, immediately after excision, were placed into electron microscopy fixative (2.5% glutaraldehyde, 2.0% paraformaldehyde, 0.025% calcium chloride in a 0.1 M sodium cacodylate buffer, pH 7.4) for 3 h at room temperature and then placed in cacodylate buffer. The nerves were postfixed with osmium tetroxide, en bloc stained with 2.0% uranyl acetate, dehydrated in a graded ethanol series, embedded in pure epoxy resin, and polymerized overnight at 608C in a Leica Lynx automatic tissue processor. For light microscopy, 1-mm-thick sections were cut using glass knives and a Sorvall MT-1 (Dupont) ultramicrotome, floated on water droplets on glass slides, and dried in a humidity chamber on a warm hot plate. Toluidine blue stain (0.5% toluidine blue in aqueous 0.5% sodium borate) was pipetted over the sections and placed onto the hot plate until a slight gold rim could be seen around the stain droplet. The sections were rinsed in a stream of distilled water, dried, coverslipped, and examined. Representative nerves were chosen, the blocks trimmed, and thin sections, 0.25 mm, were cut using a diamond knife and an LKB 2088 ultramicrotome and placed on copper grids. Sections were stained with lead citrate and examined in a transmission electron microscope (FEI Morgagni). Images were captured with a 2K digital charge-coupled camera (Advanced Microscopy Techniques).
Statistical Analysis
We used Microsoft Excel and GraphPad Prism for statistic analysis. Tumor size and neurologic scores were compared using a 2-tailed Student's t-test (unpaired). Survival was analyzed using Kaplan-Meier curves compared by a log-rank (Mantel-Cox) test.
Results
Sciatic Nerve MPNST Model
We have established 2 nerve sheath tumor models: (i) mouse MPNST cell lines derived from spontaneously arising tumors in Nf1/Trp53 heterozygous transgenic mice implanted into immunocompetent C57BL6/129SVSVImJ hybrid mice and (ii) human MSLCs implanted into immunodeficient mice. We compared the growth of 6 mouse MPNST cell lines after subcutaneous and intrasciatic nerve implantation (Fig. 1) . While fewer cells were implanted into the sciatic nerve, the rate of growth was similar to that seen after subcutaneous implantation, except that M5 was extremely slow and M3 was more rapid and comparable to M6 in the sciatic nerve (Fig. 1A and B) . A representative M2 sciatic nerve tumor at day 23, along with the normal sciatic nerve in the right hind limb, is illustrated in Fig. 1D . Histological analysis of M2 and M3 tumors showed malignant poorly differentiated tumors composed of anaplastic cells with prominent nucleoli, often arranged in fascicles, with features of sarcoma ( Supplementary Fig. S2 ). Previously we reported that M1 and M2, forming the most rapidly growing tumors, had high Ras activation, in contrast to M3 -M5, with low Ras activation. 36 Human MSLCs also formed tumors after implantation into the sciatic nerve, but at a much slower rate than the mouse MPNST cells (Figs. 1E and 3B). Human MSLC tumors were poorly differentiated and highly mitotic and diffusely infiltrated along nerve axons ( Supplementary Fig. S3 ). As would be expected, mice developed neurologic deficits as the tumors grew. To quantify this, we developed a neurologic scoring system of hind-limb function, which allowed us to follow the clinical consequences of tumor growth and treatment (Supplementary Fig. S4 ). The neurologic deficit typically arose before the tumor was detectable by external measurement (Figs. 3, 5 , and 7) and therefore provided a useful measure of when tumors were established and when therapy could be initiated.
G47D Treatment of Human MSLC-derived Tumors
To examine G47D replication and spread in MSLCs, we infected S462 MSLC spheres with G47D-mCherry and followed virus spread in vitro by fluorescence microscopy. S462 spheres were permissive to oHSV infection, and virus efficiently spread throughout the spheres (Fig. 2A) . To evaluate G47D efficacy in vivo, human Antoszczyk et al.: oHSV treatment of sciatic nerve MPNST S462 MSLCs were implanted into the sciatic nerve of athymic mice. When neurologic score decreased from 10 to 8 or 9 points, the tumor-bearing sciatic nerve was surgically exposed and a single injection of PBS or G47D was administered. Two G47D doses were compared, G47D-hi (2 ×10
6 plaque-forming units [pfu]) and 10-fold lower G47D-lo (2 × 10 5 pfu). In the PBS control group, all tumors exhibited rapid growth such that the mice had to be sacrificed before tumors were externally palpable in the G47D-treated groups (Fig. 3B) . Virus spread within tumors was detected by X-Gal staining of G47D-infected cells. The ) were implanted into the sciatic nerve of athymic (nu/nu) mice. G47D-lo (2 ×10 5 pfu; n ¼ 6), G47D-hi (2 ×10 6 pfu; n ¼ 7), or PBS (n ¼ 6) in 2 mL was injected on day 56. The mean internal diameters+SD of the tumors at injection were: mock, 39+5.0; G47D-lo, 35+5.9; G47D-hi, 32+8.3. (A) Mean neurologic score+SD; P , .05 mock vs G47D-lo or -hi on days 5 -15; G47D-hi vs G47D-lo on days 15, 19, 26 -43. (B) Tumor growth for individual mice. Three mice in G47D-hi and -lo groups had undetectable tumors (,30 mm 3 ) and are not included. (C) Survival; P , .002 (log-rank test) G47D vs mock. Median survival was 23 days for mock and 64 days for G47D. One mouse in the G47D-lo group was found dead on day 30 and in the G47D-hi group due to obstruction on day 78 (no apparent tumors). Experiment was terminated on day 103 after virus injection. (D) Established tumors were intratumorally injected with G47D (3 ×10 6 in 2 mL), mice were sacrificed, and tumor was isolated 5 days later. Fixed tumor was stained by X-Gal histochemistry (infected cells stain blue). Left, whole tumor. Right, coronal section. (E) Histology (hematoxylin-eosin stain) of tumors treated on day 61 (PBS and G47D-hi) and harvested on day 68. (F) Tumor-bearing sciatic nerves after treatment (sacrifice on day 103). G47D-lo on left and G47D-hi on right.
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G47D injection site is easily visible (Fig. 3D , left, blue), and sectioning through the tumor demonstrates efficient spread (Fig. 3D , right, blue) at 5 days postinjection. Histology of tumors harvested 7 days after G47D-hi injection showed large areas of necrosis compared with controls (Fig. 3E) . While the decrease in neurologic score was significantly less in G47D-hi compared with G47D-lo (Fig. 3A) , there was no difference in median survival between the treatment groups (Fig. 3C) . However, both doses resulted in about 30% long-term survivors, compared with 0% in the PBS group, with the sciatic nerves from the surviving G47D-treated mice showing no tumor (Fig. 3F) .
Safety of G47D After Sciatic Nerve Injection
In light of the significant efficacy exhibited in sciatic nerve tumors, we examined the safety of direct sciatic nerve injection of G47D. G47D (2.5 × 10 6 pfu) or PBS (vehicle) was injected into the normal left sciatic nerve of athymic mice without tumors. All G47D-injected mice gained weight over the observation period, which did not differ from that of the control vehicle-injected mice (Fig. 4A) . Four G47D-injected mice experienced a transient small decrease in neurologic score that returned to normal (score ¼ 10), while 2 mice exhibited a small deficit long term, similar to what was seen with the vehicle-injected mice (Fig. 4B) . When the experiment was terminated (after 121 days for G47D and 70 days for vehicle), the injected left sciatic nerves and the noninjected right sciatic nerves were removed for histological evaluation using plastic embedded sections and electron microscopy examination. The G47D-injected sciatic nerves did not exhibit any ultrastructural abnormalities; there was no evidence of axonal loss, demyelination, axonal degeneration, or regenerating clusters compared with the noninjected sciatic nerves, with the exception of focal needle track damage that was also seen in the PBS-injected nerves (Fig. 4C, Supplementary Fig. S5 ).
Treatment of Immunocompetent MPNST Model
The sensitivity of the mouse MPNST cell lines to G47D varied over a large range. M1 was the most permissive, followed by M2 and M3, while M4 to M6 were relatively resistant (Fig. 2B) . All cell lines were similarly sensitive to wild-type HSV-1 36 and expressed the herpesvirus entry mediator C (HveC; data not shown). We therefore decided to use M2 (G47D permissive but not too rapid tumor growth) to test treatment. M2 sciatic nerve tumors were apparent prior to treatment (Fig. 5A ) in proximity to the axon bundles (Fig. 5B , white arrow). G47D was able to replicate and spread in the tumors, but not in the nerves, as illustrated by X-Gal staining of tumor sections 2 days postinjection (Fig. 5B, blue stain) . Because of the rapid growth of the M2 tumors, we treated tumors with a single injection of G47D (3 × 10 6 pfu) or PBS on day 10. Compared with control, G47D treatment significantly delayed tumor growth (Fig. 5C ), improved neurologic scores (Fig. 5D) , and extended survival (Fig. 5E ). While median survival increased only from 40 days for PBS to 51 days for G47D, importantly 30% of G47D-treated mice survived long term. The 5 surviving mice did not have macroscopically detectable tumor and exhibited good neurologic scores of 8 -10. Histological examination of toluidine blue stained sections from treated sciatic nerves from 4 of these mice also revealed no evidence of tumor. In addition, the only ultrastructural abnormalities were areas of edema and some infiltration of lymphocytes and mast cells, which were also present in a mouse with a normal neurologic score of 10 ( Supplementary Fig. S6 ).
Improved Antitumor Efficacy in Immunocompetent Models
With "Armed" G47D
Expression of PF4 or IL-12 was previously shown not to alter the replication of G47D. 13, 31 G47D-PF4 was previously tested in M2 subcutaneous tumors in immunodeficient mice and demonstrated significant but limited inhibition of tumor growth over G47D-empty. 13 Thus, we examined the in vivo efficacy of G47D-PF4 in M2 sciatic nerve tumors in immunocompetent mice. When the median neurologic score decreased to about 8 (day 11), the sciatic nerve was surgically exposed and G47D-PF4 or G47D-empty (no transgene) or mock was injected into the tumor, followed by a second injection on day 17. At the second injection, there was a significant increase in the internal tumor volume of PBS-versus virus-injected tumors (Fig. 6A) . While both G47D-empty and G47D-PF4 significantly reduced tumor growth (data not shown) and neurologic deficit (Fig. 6B ) compared with PBS, PF4 expression did not significantly 5×10 4 ) were implanted into the sciatic nerve of C57BL6/129SVSVImJ hybrid mice. G47D-empty (n ¼ 7), G47D-PF4 (2×10 7 pfu; n ¼ 7), or PBS (n ¼ 7) in 2 mL was injected on days 11 and 17 (arrows). (A) Tumor size was measured internally. On day 17, P , .0001 PBS vs treated. (B) Neurologic score; P , .01 PBS vs G47D-empty or G47D-PF4 on days 17, 21, and 24; P . .1 G47D-empty vs G47D-PF4. (C) Survival; P , .01 mock vs G47D-empty, P , .005 PBS vs G47D-PF4, P , .05 G47D-empty vs G47D-PF4.
Antoszczyk et al.: oHSV treatment of sciatic nerve MPNST alter these parameters. However, G47D-PF4 did significantly extend survival compared with G47D-empty (Fig. 6C) , with median survival of 28, 31, and 38 days for PBS, G47D-empty, and G47D-PF4, respectively. In this experiment the M2 tumors grew very rapidly compared with those in Fig. 5 , and treatment was initiated at a lower median neurologic score (8 vs 9), which may explain the difference in efficacy.
To examine the impact of IL-12 expression, we used M3 tumors, which grow more slowly than M2 (Fig. 1B) . Treatment was initiated when the median neurologic score decreased to 8.4 (day 31 after implantation), with a second injection on day 6. Both G47D-empty and G47D -IL12 significantly inhibited tumor growth and decreased neurologic deficits compared with PBS ( Fig. 7A and B ). There were no externally measurable tumors in the G47D-IL12 treated group until day 17, compared with day 10 for the PBS and G47D-empty groups (Fig. 7B) . G47D -IL12 was significantly better than G47D-empty in all outcome measures. The median survival was 21, 28, and 33 days after treatment for PBS, G47D-empty, and G47D -IL12, respectively, with 2 mice in the G47D -IL12 group surviving at least 9 weeks after treatment (Fig. 7C ).
Discussion
The poor prognosis for patients with MPNST and the low efficacy of tested pharmacological agents makes it important to identify and evaluate new treatments for these tumors. Here we describe 2 new orthotopic MPNST models that we used to evaluate oHSV efficacy: (i) mouse MPNST cells, isolated from spontaneously arising tumors in NF-cis (Nf1 +/2 /Trp53 +/2 ) transgenic mice, 10 implanted into the sciatic nerve of syngeneic immunocompetent mice; and (ii) human S462 MSLCs 20 implanted into the sciatic nerve of immunodeficient mice. In MPNST patients, the most common nerve of origin is the sciatic nerve. 39 The sciatic nerve in mice is surgically accessible and of sufficient size to accommodate tumor cell injection, and tumor growth/nerve damage can be evaluated clinically by hind-limb and paw deficits. The mouse MPNST cells varied significantly in their growth kinetics, after both subcutaneous or sciatic nerve implantation. Subcutaneous implantation in nude mice revealed similar growth kinetics to implantation in immunocompetent mice, with M1 being the fastest and M3 the slowest (data not shown). The only major difference after sciatic nerve implantation was the extremely slow growth of M5. The human MSLCs formed sciatic nerve tumors more slowly than the mouse cells. This is the first description of a cancer stem cell -like peripheral nerve tumor xenograft model. Recently, a sciatic nerve human MPNST model was used to demonstrate the effectiveness of tamoxifen. 40 Tumorinitiating cells have been isolated from MPNST arising in transgenic Nf1 +/2 /Ink4a/Arf 2/2 mice with very high frequency. 41 Whether these cells have stemlike properties or how similar they are to our human MSLCs is unknown. Human MSLCs are extremely difficult to isolate (M. Spyra and V. F. Mautner, unpublished data), and there are only a few human MPNST cell lines that are tumorigenic. 42, 43 HSV is a neurotrophic virus, which after footpad inoculation of wild-type virus invades the CNS via the sciatic nerve, causing paralysis and death. 44 Direct injection of wild-type HSV into the sciatic nerve causes demyelination and inflammation at early time points, followed by lethal encephalitis. 45 -47 Oncolytic HSVs, such as G207 and G47D, are engineered to minimize neurotoxicity 27, 48 and thus should be appropriate for treating peripheral nerve tumors or tumors invading peripheral nerves. There are several ongoing clinical trials using oHSV as a single therapeutic agent against a variety of tumors, with no evidence of adverse events and indications of efficacy. 24 We found that injection of G47D into the sciatic nerves of HSV-sensitive immunodeficient athymic mice was nonpathogenic, with mice exhibiting similar minor, transient neurologic deficits and needle track damage as the PBS-injected mice. Sciatic nerves from G47D-treated tumors in "cured" immunocompetent mice did not exhibit virus pathology. A different oHSV expressing IL-12 (MOO2) was recently found to be safe after intracerebral injection in susceptible nonhuman primates. 49 Many solid tumors, such as prostate and pancreatic cancers, have a propensity for neural invasion that is often associated with poor outcomes. 50 In a previous model of peripheral nerve sheath tumors, human neuroblastoma cells were implanted into the sciatic nerve. A single intratumoral injection of G207, when mice exhibited hind-limb dysfunction, delayed functional decline and prolonged survival. 46 Oncolytic HSV NV1023 was shown to effectively treat mice implanted with human pancreatic and prostate cancer cells in the sciatic nerve while preserving nerve function. 47, 51 Here we describe the first successful ) were implanted into the sciatic nerve of C57BL6/129SVSVImJ hybrid mice. G47D-empty (n ¼ 12), G47D -IL12 (n ¼ 12) (9 ×10 5 pfu), or PBS (n ¼ 10) in 2 mL was injected on days 0 (31 days after implantation) and 6 (arrows). Data are combined from 2 experiments. (A) Neurologic score; P , .01 mock vs G47D-empty or G47D -IL12 on days 10 and 14, P , .001 G47D-empty vs G47D-IL12 on days 14 -21 (unpaired t-test). (B) Tumor size. In the G47D-IL12 group, there were no tumors measurable externally on days 10 and 14. P , .003, PBS vs G47D-empty on day 14, P , .0001 G47D-IL12 vs G47D-empty on day 17 (unpaired t-test). (C) Survival; P , .005 mock vs G47D-empty and G47D-IL12, and G47D-IL12 vs G47D-empty.
Antoszczyk et al.: oHSV treatment of sciatic nerve MPNST treatment of orthotopic MPNST implant models with oHSV. Novel features of our 2 sciatic nerve models are the use of mouse MPNST in immunocompetent mice and human MSLCs in nude mice. We developed a neurologic scoring scheme for hind-limb deficit, which allowed us to monitor tumor growth prior to externally discernible tumors.
A number of oHSV vectors have been evaluated by us and others in various MPNST models. The Cripe laboratory has tested the anti-MPNST activity of different oHSVs in immunodeficient mice bearing subcutaneous or intraperitoneal human MPNST xenografts. 42, 52, 53 For example, in a subcutaneous model with S462.TY cells, similar to the MSLC parental cells, treatment with a G207-equivalent oHSV increased survival by about 25%. 52 In this model, an armed oHSV-expressing tissue inhibitor of matrix metalloproteinase 3 (rQT3) further extended survival more than 2-fold. 52 We previously described the treatment of subcutaneously implanted mouse M2 tumors in immunodeficient mice with "armed" G47D expressing dominant-negative FGF receptor (dnFGFR) or PF4.
12,13 G47D alone inhibited tumor growth to a small but significant extent, whereas transgene expression (dnFGFR or PF4) further inhibited tumor growth, which was associated with a .4-fold decrease in microvascular density.
12, 13 Here, we found that G47D was more efficacious in the M2 immunocompetent sciatic nerve model, with about a third of the treated mice surviving long term. This suggests possible immune-mediated effects, as have been reported for oHSV in other mouse syngeneic models. 54 -57 PF4 expression prolonged survival in the M2 model compared with G47D-empty. In the mouse M3 model, immunomodulatory IL-12 expression increased oHSV efficacy; reducing the rate of neurologic decline, delaying tumor growth, and extending survival. G47D -IL12 was also shown to prolong survival in a syngeneic glioblastoma stem cell tumor model, with IL-12 expression in the tumor inducing IFN-g synthesis. 31 Thus arming G47D with PF4 or IL12 transgenes improved antitumor efficacy in immunocompetent MPNST models, with IL-12 producing a small number of long-term survivors.
In conclusion, we demonstrate the efficacy of oHSV G47D in the treatment of both human and mouse syngeneic orthotopic MPNST models and its lack of pathogenicity after sciatic nerve injection. G47D has previously been shown to effectively treat breast, prostate, and rectal carcinomas 30, 58, 59 and thus should be considered for the treatment of patients with neural invasion of these cancers. Human MSLC implantation into the sciatic nerve provides a new representative MPNST model that should be very useful in testing novel therapeutics for MPNST. The orthotopic immunocompetent MPNST model will be of great value in testing immunotherapeutic strategies for this debilitating tumor, which is often metastatic, and complement the use of genetically engineered mouse models. 9 The enhanced efficacy of G47D -IL12 in this model indicates that other immunotherapies for MPNST, as well as combinations with immunogenic chemotherapy, should be evaluated, and provides compelling support for clinical translation.
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